Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P40225
UPID:
TPO_HUMAN
Alternative names:
C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; Myeloproliferative leukemia virus oncogene ligand
Alternative UPACC:
P40225; A1L3Y0; B7ZLR8; B9EGA8; Q13020; Q15790; Q15791; Q15792
Background:
Thrombopoietin, also known as the c-mpl ligand, plays a pivotal role in hematopoiesis by regulating the proliferation and maturation of megakaryocytes, leading to platelet formation. It is recognized as the primary physiological regulator of circulating platelets, acting at a late stage of megakaryocyte development.
Therapeutic significance:
Thrombocythemia 1, a myeloproliferative disorder characterized by excessive platelet production, is directly linked to variants affecting the gene encoding Thrombopoietin. This connection underscores the protein's potential as a target for therapeutic intervention in managing thrombotic episodes and spontaneous hemorrhages associated with the disease.